LORL yields 189.31% · PFE yields 6.20%● Live data
📍 LORL pulled ahead of the other in Year 1
Combined, LORL + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LORL + PFE for your $10,000?
Loral Space & Communications Inc., a satellite communications company, offers satellite-based communications services to the broadcast, telecom, corporate, and government customers worldwide. As of December 31, 2019, the company provided satellite services to its customers through a fleet of 16 in-orbit geostationary satellites; and owned the Canadian Ka-band payload on the ViaSat-1 satellite. It also offers video distribution and direct-to-home (DTH) video, as well as end-to-end communications services using satellite and hybrid satellite-ground networks; and broadcast services, including DTH, video distribution and contribution, and satellite transmission services for the broadcast of video news, sports, and live event coverage. In addition, the company provides telecommunication carrier and integrator services; maritime and aeronautical services; satellite services to the Canadian government; two-way broadband Internet services; communications services to the on and off shore oil and gas, and mining industries; and satellite operator services. Further, it is involved in the installation and maintenance of the end user terminal; maintenance of the VSAT hub; and provision of satellite capacity. Additionally, the company offers consulting services related to space and earth, government studies, satellite control services, and research and development; and X-band communications services to the United States, Spanish, and allied government users. Loral Space & Communications Inc. was founded in 1996 and is headquartered in New York, New York.
Full LORL Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.